Atricure Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Atricure Inc's ROI in the second quarter of 2026?
Atricure Inc achieved a return on average invested assets (ROI) of 1.84 % in its second quarter of 2026, this is above ATRC's average return on investment of -8.4%.
Atricure Inc invested over the 12 months ending in its second quarter of 2026 $574 million

ROI has improved compared to -0.82% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 10 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 1669 to 2543.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	6.93 %	4.58 %	2.73 %	0.86 %	1.14 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	595	571	573	558	540
Return On Investment (TTM)	1.84 %	-0.82 %	-2.08 %	-5.32 %	-6.77 %
ATRC's Overall Ranking	# 2543	# 1669	# 2154	# 2570	# 0
Seq. Investment Change TTM	2.44 %	1.84 %	1.7 %	0.79 %	0.18 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	11	-5	-11	-29	-36

ATRC Company Profile >> Back to ATRC Roi Comparisons >> See Annual ATRC Return On Investment

Return On Investment ATRC's Ranking
Within:	No.
Industry	# 5
Sector	# 11
Overall	# 2543

Return On Investment Statistics
High	Average	Low
9.7 %	-8.4 %	-22.87 %
(Jun 30 2022)

News about Atricure Inc Return on Investment ROI

Evolving Recovery AtriCures cryoSPHERE MAX Probe Sets a New Standard in Post-Operative Pain Management

October 15, 2024

In the ever-evolving landscape of medical technology, innovation has become the heartbeat of progress. This rings particularly true in the field of surgical procedures and post-operative care, where patient comfort and recovery are paramount. AtriCure, Inc. (Nasdaq: ATRC), a leader in surgical treatments for atrial fibrillation and left atrial appendage management, is poised to reshape post-operative pain management with its latest launch: the cryoSPHERE MAX cryoablation probe. Unveiled in MASON, Ohio, the cryoSPHERE MAX probe is more than just a new tool in the operating room it s a game-changer. Designed with a larger ball tip, this cutting-edge device significantly enhances Cryo Nerve Block therapy (cryoNB), a technique that has garnered attention for its ability to minimize post-surgical discomfort and expedite recovery times. The magic lies in its engineering; compared to AtriCure s first-generation probes, the cryoSPHERE MAX reduces freeze times by an impressive 50%. Why is this significant For starters, post-operative pain management has long been a critical challenge in surgeries, affecting patient satisfaction and recovery durations. Traditional pain relief methods often involve systemic medications with side effects that can hinder rather than help. AtriCure s cryoSPHERE MAX introduces a localized solution freezing the nerves responsible for pain without inundating patients with pharmaceuticals. This targeted approach not only provides immediate relief but does so with a reduced risk of complications associated with general pain management strategies.The advantages of the cryoSPHERE MAX probe extend beyond just performance. It also signifies a shift toward more patient-centric care in surgical environments. As healthcare professionals increasingly recognize the value of personalized medicine, innovations like the cryoSPHERE MAX are at the forefront, promoting approaches that center around the individual needs of patients. This dedication to patient welfare aligns seamlessly with current trends in healthcare, where enhancing patient experiences is just as crucial as improving clinical outcomes.

Financial Statements
Atricure Inc's II. Quarter Investments	$ 595 Millions	ATRC's Balance sheet
Atricure Inc's II. Quarter Income	$ 9 Millions	Quarterly ATRC's Income Statement
ATRC's Income by Division		See ATRC's Income by Division

ATRC Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	573	536	539	527	559
Y / Y Investment Growth	6.86 %	-0.64 %	2.34 %	-5.69 %	-16.01 %
Net Income in Millions	-11	-45	-30	-46	50
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-2 %	-8.34 %	-5.64 %	-8.82 %	8.98 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ATRC's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ATRC's Competitors
Subscribers only: Roi for Atricure Inc's Suppliers
Subscribers only: Return On Investment for ATRC's Customers

Other Ratios
ATRC's Roa	ATRC's Inventory Turnover Ratio	ATRC's Growth Rates	ATRC's Dividend Statistics
	ATRC's Profitability Ratios	ATRC's Asset Turnover Ratio	ATRC's Dividend Growth
ATRC's Roe	ATRC's Valuation Ratios	ATRC's Financial Strength Ratios	ATRC's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Henry Schein Inc	5.06 %
Cadre Holdings inc	4.92 %
Haemonetics Corporation	4.91 %
The Pennant Group Inc	4.62 %
Vaso Corporation	4.40 %
Zimmer Biomet Holdings Inc	3.97 %
U S Physical Therapy Inc	3.91 %
Privia Health Group Inc	3.90 %
Integer Holdings Corporation	3.88 %
Ardent Health Inc	3.74 %
Collegium Pharmaceutical Inc	3.72 %
Merck and Co Inc	3.24 %
Community Health Systems Inc	3.12 %
National Vision Holdings Inc	2.99 %
Teva Pharmaceutical Industries Limited	2.66 %
Lifestance Health Group Inc	2.61 %
Conmed Corporation	2.57 %
Pfizer Inc	2.53 %
Mimedx Group Inc	2.38 %
Bio rad Laboratories Inc	2.34 %
Lifemd Inc	2.32 %
Alkermes Plc	2.31 %
Becton Dickinson And Company	2.22 %
Revvity Inc	2.18 %
Envista Holdings Corporation	2.06 %
Immucell Corporation	1.95 %
Atricure Inc	1.84 %
Black Hawk Acquisition Corporation	1.79 %
Omada Health Inc	1.70 %
Arvinas Inc	1.53 %

Date modified: 2026-09-26T07:10:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.